Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and developing transformative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovery of novel compounds that work through a unique mechanism to modulate — rather than block or over-activate — NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. We believe leveraging the therapeutic advantages of this differentiated mechanism will drive a paradigm shift in the treatment of numerous disorders of the brain and nervous system.
Our current clinical development programs span painful diabetic peripheral neuropathy, fibromyalgia, post-traumatic stress disorder, and cognitive impairment. We are also developing a robust library of preclinical candidates.